Justus Duyster

The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.

M. Hallek, J. Duyster, W. Aulitzky, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The anticancer drug imatinib induces cellular autophagy

J. Duyster, T. Yoshimori, H. Elsässer, 2007, Leukemia.

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro

R. Engh, C. Peschel, J. Duyster, 2011, Oncogene.

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

F. Lordick, C. Peschel, J. Duyster, 2005, British Journal of Cancer.

Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain.

J. Wang, R. Baskaran, J. Duyster, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

Y. Wang, P. Paschka, J. Duyster, 2005, Leukemia.

Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model

R. Braren, A. Feuchtinger, A. Walch, 2014, Oncogene.

Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

C. Peschel, J. Duyster, T. Decker, 2005, Leukemia.

Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.

C. Miething, J. Duyster, W. Aulitzky, 2001, Blood.

Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib

C. Haferlach, C. Peschel, J. Duyster, 2007, Bone Marrow Transplantation.

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

F. Lordick, C. Peschel, J. Duyster, 2005, British Journal of Cancer.